{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T02:56:02Z","timestamp":1722048962105},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T00:00:00Z","timestamp":1450310400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00280-015-2936-z","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T08:56:28Z","timestamp":1450342588000},"page":"429-437","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression"],"prefix":"10.1007","volume":"77","author":[{"given":"Ji\u0159ina","family":"Mart\u00ednkov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Bl\u00e1ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ond\u0159ej","family":"Kube\u010dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Mal\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159\u00ed","family":"\u0160pa\u010dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Bezou\u0161ka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva Selke","family":"Krulichov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislav","family":"Filip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,17]]},"reference":[{"issue":"12 Pt 1","key":"2936_CR1","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46(12 Pt 1):6387\u20136392","journal-title":"Cancer Res"},{"issue":"2","key":"2936_CR2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","volume":"161","author":"T Lammers","year":"2012","unstructured":"Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-)clinical progress. J Control Release 161(2):175\u2013187","journal-title":"J Control Release"},{"issue":"7","key":"2936_CR3","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","volume":"16","author":"DW Northfelt","year":"1998","unstructured":"Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16(7):2445\u20132451","journal-title":"J Clin Oncol"},{"issue":"14","key":"2936_CR4","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312\u20133322","journal-title":"J Clin Oncol"},{"issue":"3","key":"2936_CR5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O\u2019Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Indar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomaczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15(3):440\u2013449","journal-title":"Ann Oncol"},{"issue":"9","key":"2936_CR6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1634\/theoncologist.2013-0126","volume":"18","author":"JM Gibson","year":"2013","unstructured":"Gibson JM, Alzghari S, Ahn C, Trantham H, La-Beck NM (2013) The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. Oncologist 18(9):1022\u20131031","journal-title":"Oncologist"},{"issue":"3","key":"2936_CR7","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1124\/jpet.103.053413","volume":"306","author":"GJ Charrois","year":"2003","unstructured":"Charrois GJ, Allen TM (2003) Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 306(3):1058\u20131067","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2936_CR8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.nano.2014.08.010","volume":"11","author":"MK Sabnani","year":"2015","unstructured":"Sabnani MK, Rajan R, Rowland B, Mavinkurve V, Wood LM, Gabizon AA, La-Beck NM (2015) Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses. Nanomedicine 11(2):259\u2013262","journal-title":"Nanomedicine"},{"issue":"2","key":"2936_CR9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jca.20229","volume":"25","author":"G P\u00fctz","year":"2010","unstructured":"P\u00fctz G, Schmah O, Eckes J, Hug MJ, Winkler K (2010) Controlled application and removal of liposomal therapeutics: effective elimination of pegylated liposomal doxorubicin by double-filtration plasmapheresis in vitro. J Clin Apher 25(2):54\u201362","journal-title":"J Clin Apher"},{"issue":"337","key":"2936_CR10","first-page":"1","volume":"11","author":"J Eckes","year":"2011","unstructured":"Eckes J, Schmah O, Siebers JW, Groh U, Zschiedrich S, Rautenberg B, Hasenburg A, Jansen M, Hug MJ, Winkler K, P\u00fctz G (2011) Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial). BMC Cancer 11(337):1\u201311","journal-title":"BMC Cancer"},{"issue":"10","key":"2936_CR11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1177\/106002809703101003","volume":"31","author":"SD McClellan","year":"1997","unstructured":"McClellan SD, Whitaker CH, Friedberg RC (1997) Removal of vancomycin during plasmapheresis. Ann Pharmacother 31(10):1132\u20131136","journal-title":"Ann Pharmacother"},{"key":"2936_CR12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosissup.2015.02.009","volume":"18","author":"M Blaha","year":"2015","unstructured":"Blaha M, Andrys C, Langrova H, Studnicka J, Drsata J, Lanska M, Blaha V, Zak P (2015) Changes of the complement system and rheological indicators after therapy with rheohemapheresis. Atheroscler Suppl 18:140\u2013145","journal-title":"Atheroscler Suppl"},{"issue":"2","key":"2936_CR13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0378-4347(01)00151-7","volume":"757","author":"R Bellott","year":"2001","unstructured":"Bellott R, Pouna P, Robert J (2001) Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome. J Chromatogr B Biomed Sci Appl 757(2):257\u2013267","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"2936_CR14","unstructured":"Hedaya MA (2012) Basic pharmacokinetics, second edition in pharmacy education series. CRC Press: Hoboken, p 1. Online resource: 581\u00a0p"},{"issue":"3","key":"2936_CR15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00280-014-2514-9","volume":"74","author":"MJ Boers-Sonderen","year":"2014","unstructured":"Boers-Sonderen MJ, van Herpen CM, van der Graaf WT, Desar IM, van der Logt MG, de Beer YM, Ottedvanger PB, van Erp NP (2014) Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) Caelyx(R). Cancer Chemother Pharmacol 74(3):457\u2013463","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2936_CR16","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","volume":"18","author":"D Lorusso","year":"2007","unstructured":"Lorusso D, Di Stewfano A, Carone V, Fagotti A, Pisconti S, Scambia G (2007) Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot\u2019 syndrome). Ann Oncol 18(7):1159\u20131164","journal-title":"Ann Oncol"},{"issue":"5","key":"2936_CR17","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","volume":"89","author":"O Lyass","year":"2000","unstructured":"Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89(5):1037\u20131047","journal-title":"Cancer"},{"key":"2936_CR18","first-page":"2607","volume":"6","author":"CC Tsai","year":"2011","unstructured":"Tsai CC, Chang CH, Chen LC, Chang YJ, Lan KL, Wu YH, Hsu CW, Liu IH, Ho CL, Lee WC, Ni HC, Chang TJ, Ting G, Lee TW (2011) Biodistrubution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. Int J Nanomedicine 6:2607\u20132619","journal-title":"Int J Nanomedicine"},{"issue":"4","key":"2936_CR19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/jca.10074","volume":"18","author":"PE Kintzel","year":"2003","unstructured":"Kintzel PE, Eastlund T, Calis KA (2003) Extracorporeal removal of antimicrobials during plasmapheresis. J Clin Apher 18(4):194\u2013205","journal-title":"J Clin Apher"},{"issue":"4","key":"2936_CR20","first-page":"987","volume":"54","author":"A Gabizon","year":"1994","unstructured":"Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54(4):987\u2013992","journal-title":"Cancer Res"},{"issue":"2","key":"2936_CR21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/14737140.2.2.143","volume":"2","author":"T Tejada-Berges","year":"2002","unstructured":"Tejada-Berges T, Granai CO, Gordinier M, Gajewski W (2002) Caelyx\/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther 2(2):143\u2013150","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2936-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2936-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2936-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:07:39Z","timestamp":1559038059000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2936-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,17]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["2936"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2936-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,17]]}}}